Clinical manifestation and gene mutation analysis of VHL syndrome families with first diagnosis of cerebral hemangioblastoma
10.3760/cma.j.issn.1674-6554.2017.06.016
- VernacularTitle:以脑血管母细胞瘤首诊的VHL综合征家系临床表现及基因突变分析
- Author:
Yuhao ZHOU
;
Jian LIU
;
Minghao DONG
;
Luqian FENG
;
Liangzhao CHU
- Keywords:
Central nervous system hemangioblastoma;
VHL syndrome;
Genotype Analysis
- From:
Chinese Journal of Behavioral Medicine and Brain Science
2017;26(6):560-563
- CountryChina
- Language:Chinese
-
Abstract:
Objective To detect the mutations of Von Hippel-Lindau (VHL) gene via analyzing the prevalence of family members of VHL syndrome,clinical diagnosis and treatment,and gene analysis of patients with hemangioblastoma.methods All members of the VHL syndrome family members improved all relevant tests and plotted the family map.5 ml peripheral blood was extracted for gene sequencing,and the sequencing Result s were compared with the reported mutations of VHL gene in NCBI database.Result s(1)Analysis of clinical data of four members of the family:Ⅰ-2,Ⅱ-1,Ⅱ-5 suffering from central nervous system hemangioblastoma, Ⅱ-3 with pancreatic,retinopathy and pheochromocytoma,and Ⅱ-5 also combined with kidney,pancreatic lesions.The second generation of patients in the family have been treated surgically.(2)Gene sequencing Result s showed that all subjects in the test had the same mutation:exon2 109 sequence ATATCACACTGCCA was deleted and termination codon UGA appeared in exon 502.Conclusion Through the mutations of the VHL syndrome family,it is found that the family mutation type is a new mutation.For patients with central nervous system hemangioblastoma-based should be suspected of the disease and improve the family history survey.Once the diagnosis of familial VHL syndrome patients are confirmed,it is necessary to inform the other members of the family for clinical screening,and carry out genetic testing to reduce the harm of the disease to the greatest extent.
